This report gathers perceptions and concerns from female sex works in Kenya concerning access to microbicides and PrEP. It highlights the importance of engaging this key population in product research and development.
We can use it if it’s made for us: Kenyan Sex workers perspectives and Voices on Microbicides and PrEP
Px Wire July-September 2009, Vol. 2, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue is designed to provide background and perspectives on some of the key issues and questions that have emerged as work around understanding and interpreting the results of the Thai trial moves forward.
Px Wire April-June 2009, Vol. 2, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue features multiple trial updates, including a review of the key findings from a trial of HSV-2 suppression. The issue also features a discussion of the results of the HPTN 035 microbicide trial (which tested PRO 2000 and BufferGel) and preparations for the upcoming results of MDP 301, also testing PRO 2000 gel. Additionally, this issue provides information on new trials including HVTN 505 (described in this year’s first issue of Px Wire), which began screening participants in June, a new trial on intermittent PrEP scheduled to begin in July, and research to test a nipple shield to help prevent HIV transmission during breastfeeding.
Px Wire April-June 2014, Vol. 7, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people and also explores progress in implementing oral PrEP in the nearly 24 months since the US Food and Drug Administration approved daily oral TDF/FTC (Truvada) as PrEP.
Px Wire January-March 2014, Vol. 7, No. 1
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue of Px Wire, AVAC applauds the nomination of Dr. Debbi Birx as the new US Global AIDS Coordinator. Highlights of this issue also include an examination of why the global systems for tracking voluntary medical male circumcision are lagging behind the actual progress that’s being made—and discusses ways to close this critical data gap. This issue also reviews a recent setback in cure research and what it means for next steps.
Px Wire October-December 2013, Vol. 6, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reports on a recent think tank meeting on therapeutic HIV vaccines—these vaccines would attempt to control or eliminate the virus by prompting immune responses in HIV-positive people. Also in this issue is a brief report on the recent NIAID “mini-summit” on adenovirus platforms for HIV vaccines.
Px Wire July-September 2013, Vol. 6, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This quarter, Px Wire highlights three recent developments in the field and key issues for each: the World Health Organization (WHO) prequalification of PrePex, a nonsurgical voluntary medical male circumcision device; the positive result from the study of daily oral tenofovir as PrEP for HIV prevention in people who inject drugs; and new WHO guidelines on the use of ARVs, which recommend antiretroviral treatment for all HIV-positive people with CD4 cell counts of 500 or below.
Px Wire April-June 2013, Vol. 6, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of Px Wire highlights the adherence issues raised by the VOICE trial results and introduces a tool created to help civil society influence PEPFAR annual Country Operational Plans.
Px Wire January-March 2013, Vol. 6, No. 1
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews the recent AVAC Advocacy Partners’ Forum, where partners from across sub-Saharan Africa and beyond met and discussed goals for the year ahead. This issue also covers some key content and messages from the PEPFAR Blueprint.
Px Wire October-December 2012, Vol. 5, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of Px Wire features an advocates’ guide to the “sieve analysis” from the RV144 vaccine trial. This latest follow-up investigation provided further detail about the partial protection associated with the vaccine strategy. This issue also updates readers with the latest on trials of ARV-containing vaginal rings—the next frontier in microbicide development.